A comprehensive database for cancer patient genomic and clinical data
BostonGene-Integrated Genomic Registry Study
This study is creating a detailed database of cancer patients' genetic and health information to see if it can help improve treatment outcomes for different types of cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | BostonGene Industry-sponsored |
| Locations | 1 site (Waltham, Massachusetts) |
| Trial ID | NCT04991922 on ClinicalTrials.gov |
What this trial studies
This project aims to create a detailed registry that compiles genomic, transcriptomic, molecular, and clinical characteristics of oncology patients. By collecting and analyzing this data, the study seeks to identify genomic and transcriptomic markers that can enhance clinical outcomes across various cancer types. Participants will provide clinical information linked to their genetic findings, which will be stored in a secure electronic database. The study does not involve any additional scans or procedures beyond standard care.
Who should consider this trial
Good fit: Ideal candidates include individuals with suspected or confirmed malignancy who are undergoing comprehensive genomic analysis.
Not a fit: Patients with a life expectancy of less than three months may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and outcomes for cancer patients through personalized medicine.
How similar studies have performed: Other studies have shown promise in utilizing genomic and transcriptomic data to improve cancer treatment outcomes, indicating that this approach is supported by prior research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Suspected or confirmed malignancy 2. Planned comprehensive genomic (\> 100 genes) and/or molecular analysis; or genomic and/or molecular data available from prior sequencing 3. Baseline demographics and treatment information available 4. Willingness for future contact by BIRG study personnel to provide information regarding associated cancer outcomes and treatment. 5. Signed informed consent to participate in the study. 6. Living in the United States at the time of enrollment Exclusion Criteria: Life expectancy \< 3 months
Where this trial is running
Waltham, Massachusetts
- BostonGene — Waltham, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: Nathan Fowler — BostonGene
- Study coordinator: Nathan Fowler
- Email: nathan.fowler@bostongene.com
- Phone: +1-617-658-4545
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.